TrovaGene, Inc. (NASDAQ:TROV) is set to announce its earnings results after the market closes on Tuesday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

TrovaGene, Inc. (NASDAQ:TROV) opened at 0.7256 on Tuesday. The company has a 50-day moving average of $0.75 and a 200 day moving average of $0.86. TrovaGene, Inc. has a one year low of $0.61 and a one year high of $3.95. The company’s market cap is $27.04 million.

TRADEMARK VIOLATION NOTICE: “TrovaGene, Inc. (TROV) Set to Announce Quarterly Earnings on Tuesday” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at

A number of analysts have commented on TROV shares. Maxim Group set a $4.00 price target on shares of TrovaGene and gave the company a “buy” rating in a research note on Thursday, July 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Earnings History for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.